A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

Exclusion Criteria

• •Active malignancy other than SCLC within the previous 5 years
• •Participants who have received radiotherapy less than 2 weeks prior to first dose of study medication
• •Surgical procedure or clinically significant trauma within 2 weeks of first dose of study treatment
• •Treatment with any investigational agent \<=3 weeks prior to first dose of study treatment
• •Participants with gastrectomy or pre-existing gastrointestinal disorders that may interfere with the proper absorption of the drug(s), as per conclusion of the clinical Investigator
• •Participants medicated with anti-depressants reported to have lysine-specific histone demethylase 1A (KDM1A)/lysine (K)-specific demethylase 1A (LSD1) inhibitory activity (such as tranylcypromine or phenelzine) within 28 days of treatment start
• •History of allergic reactions attributed to components of the formulated product(s)
• •History of seizure disorders
• •Participants with untreated central nervous system metastases, or history of previously treated disease. Participants must have stable hematological parameters, satisfying eligibility, platelet count must be stable for \>=2 weeks prior to study drug administration
• •Participants who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
• •Participants with evidence of electrolyte imbalance
• •Participants who are pregnant or breastfeeding
• •Participants who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
• •Participants with known bone marrow disorders which may interfere with bone marrow recovery or participants with delayed recovery from prior chemoradiotherapy
• •Participants with known coagulopathy, platelet disorder or history of non-drug-induced thrombocytopenia
• •Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)-positive participants with active infection
• •Use of strong Cytochrome P450 3A4 (CYP3A4) inducers while on study medication
• •Participants with abnormal hepatic function
• •Participants with history of clinically significant bleeding, specifically any history of intracranial hemorrhage/hemorrhagic cardiovascular accident (CVA), or participants with gastrointestinal bleeding within the 12 months prior to study entry
• •Participants receiving therapeutic anti-coagulation or anti-platelet (anti-aggregant) therapies, except for therapeutic enoxaparin or low dose aspirin. Use of subcutaneous heparin prophylaxis, including low molecular weight heparin is also permitted